PRODUCT

Adipotide (Prohibitin‑TP01)

No short description available.

Weight Loss

moderate

White Adipose Reduction
Targeted apoptosis of WAT microvasculature drives loss of adipose mass.

Metabolic

effective

Insulin Sensitivity
Improved insulin dynamics after WAT reduction in primates.

Appetitecontrol

effective

Semaglutide (GLP‑1 RA)

Monitor Combination

Potential additive dehydration/GI effects; monitor renal function (adipotide has dose‑related proximal tubule effects).

Tirzepatide (GLP‑1/GIP RA)

Monitor Combination

Overlapping weight‑loss effects; monitor kidney function, volume status, and electrolytes.

Cagrilintide (Amylin analog)

Unknown

No clinical data on co‑administration; mechanisms differ (satiety vs. adipose vasculature).

AOD‑9604

Unknown

No published data on combined use or pharmacodynamic interaction.

BPC‑157

Compatible

No known direct interaction; distinct mechanisms and targets.

CJC‑1295 / Ipamorelin

Use Caution

Metabolic effects may confound body‑composition endpoints; consider staging or separating protocols.

Melanotan II

Requires Timing

Theoretical vascular/pressor effects; if studied together, stagger dosing and monitor BP and hydration.

Nephrotoxic drugs (e.g., high‑dose NSAIDs, aminoglycosides) *

Avoid Combination

Adipotide shows dose‑dependent proximal tubule injury in primates; avoid additional renal insults.

Route:injectable

Route:injectable

Resources